Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Pilot Study to Evaluate the Molecular and Cellular Response to Treatment With Nivolumab With Either Adjuvant Ipilimumab or Relatlimab in Adult Patients With Surgically Resectable Melanoma Brain Metastases

NCT05704933 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT05704933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05704933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Pilot Study to Evaluate the Molecular and Cellular Response to Treatment With Nivolumab With Either Adjuvant Ipilimumab or Relatlimab in Adult Patients With Surgically Resectable Melanoma Brain Metastases
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 1
Overall status
Completed
Start date
June 6, 2023
Completion date
August 20, 2024
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis to brain, metastatic melanoma